Most clinical trials do not fail because the science is bad. They stall because nobody can find enough of the right patients. Oracle and AstraZeneca say they want to attack that problem with AI and real-world health data.
The two companies announced on October 20, 2026 a non-binding agreement to explore shared use cases. Nothing is committed yet, and no products, timelines or sites have been named. So this is an intention, not a deployment.
What they plan to explore
The core idea is to help care teams spot trial-eligible patients sooner and with less manual effort. AstraZeneca would contribute scientific and therapeutic expertise. Oracle would supply health data, cloud infrastructure, AI, analytics and clinical workflow tools, including its electronic health record footprint.
Initial areas under consideration are:
- Oncology
- Cardiovascular, renal and metabolic diseases
- Respiratory and immunology
- Rare diseases
A loop between research and care
The more ambitious part is a continuous learning model. Insights from trials and routine care would inform future study design, safety monitoring and treatment decisions. Today those two worlds mostly run separately, and evidence moves slowly between them.
The companies also plan shared governance, reusable technical components and agreed outcome measures. Those measures will decide whether any approach is worth extending to other diseases and regions. Oracle’s Seema Verma stressed that data use would stay under the governance of the health systems delivering care.
Why it matters
Patient recruitment is one of the costliest and slowest steps in drug development, and it limits access for patients who might benefit from a trial. Embedding eligibility screening in the workflow clinicians already use is a logical fix. It is also where Oracle, after its acquisition of Cerner, has a real structural advantage.
Still, the hard questions are ahead. How will patient data be governed and consented? Will trial matching work across messy records and busy clinics? Will health systems see enough benefit to participate? The announcement is silent on all three.
For clinicians and health system leaders, the practical signal is simple: expect more pharma-technology pairings aimed at point-of-care trial identification. Judge them on enrollment results, not press releases.